We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+12.49%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
+$410M
(+23%)
Cap. Flow
+$230M
Cap. Flow
% of AUM
10.53%
Top 10 Holdings %
Top 10 Hldgs %
65.42%
Holding
52
New
13
Increased
11
Reduced
11
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$246M |
| 2 |
Edwards Lifesciences
EW
|
+$117M |
| 3 |
AET
Aetna Inc
AET
|
+$92.4M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$90.2M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$88.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$99.7M |
| 2 |
QGENF
QIAGEN NV
QGENF
|
+$79.9M |
| 3 |
Danaher
DHR
|
+$74.4M |
| 4 |
Incyte
INCY
|
+$74.3M |
| 5 |
Zimmer Biomet
ZBH
|
+$69.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.1% |
| 2 | Financials | 9.22% |
| 3 | Materials | 1.56% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BIVV
1
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $272M | 12.49% |
+5,000,000
| New | +$246M |
|
|
AET
2
DELISTED
Aetna Inc
AET
| $201M | 9.22% |
1,575,000
+735,970
| +88% | +$92.4M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $174M | 7.99% |
1,400,000
-100,000
| -7% | -$12M |
|
4
Labcorp
LH
$25.9B
| $147M | 6.75% |
1,193,100
-145,500
| -11% | -$17.2M |
|
|
5
Edwards Lifesciences
EW
$50B
| $118M | 5.39% |
+3,750,000
| New | +$117M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $115M | 5.28% |
950,000
+688,860
| +264% | +$88.8M |
|
7
Intuitive Surgical
ISRG
$126B
| $115M | 5.27% |
1,350,000
-225,000
| -14% | -$17.8M |
|
|
8
Vertex Pharmaceuticals
VRTX
$122B
| $112M | 5.14% |
+1,025,000
| New | +$90.2M |
|
9
Merck
MRK
$321B
| $93.7M | 4.3% |
1,545,800
+951,091
| +160% | +$57.7M |
|
|
SYNH
10
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $77.9M | 3.58% |
1,700,000
+576,080
| +51% | +$28.7M |
|
11
Haemonetics
HAE
$3.85B
| $64.9M | 2.98% |
1,600,000
+450,000
| +39% | +$17.6M |
|
12
Align Technology
ALGN
$12.4B
| $60.2M | 2.76% |
525,000
+422,737
| +413% | +$42.7M |
|
13
Neurocrine Biosciences
NBIX
$18.7B
| $53M | 2.43% |
1,225,000
+236,100
| +24% | +$10.1M |
|
14
Qiagen
QGEN
$8.55B
| $50.7M | 2.33% |
+1,650,347
| New | +$50.9M |
|
15
Pacira BioSciences
PCRX
$1.06B
| $50.2M | 2.3% |
1,100,000
-475,000
| -30% | -$20.5M |
|
16
Sarepta Therapeutics
SRPT
$1.64B
| $45.9M | 2.1% |
+1,550,000
| New | +$48M |
|
17
Zoetis
ZTS
$31.9B
| $37.4M | 1.71% |
+700,000
| New | +$37.8M |
|
18
Baxter International
BAX
$13.8B
| $35M | 1.61% |
675,000
+381,350
| +130% | +$18.8M |
|
|
MON
19
DELISTED
Monsanto Co
MON
| $34M | 1.56% |
300,000
+175,000
| +140% | +$19.4M |
|
20
HCA Healthcare
HCA
$85.7B
| $28.9M | 1.33% |
325,000
+167,740
| +107% | +$14M |
|
|
ALR
21
DELISTED
Alere Inc
ALR
| $28.8M | 1.32% |
+725,000
| New | +$28.3M |
|
22
UnitedHealth
UNH
$383B
| $28.7M | 1.32% |
175,000
-232,580
| -57% | -$38.1M |
|
|
CVRS
23
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $26.2M | 1.2% |
19,981,655
| – | – |
|
24
Humana
HUM
$44B
| $25.8M | 1.18% |
+125,000
| New | +$25.8M |
|
25
Bristol-Myers Squibb
BMY
$132B
| $24.5M | 1.12% |
+450,000
| New | +$24.7M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2017 Portfolio in Review
As of Q1 2017, HealthCor Management held 52 positions worth $2.18B, up 23% from $1.77B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
HealthCor Management deployed $230M of net new capital in Q1 2017, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 5,000,000 shares worth $272M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 81% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Quest Diagnostics, an estimated $99.7M trimmed.
- HealthCor Management's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 5,000,000 shares worth $272M.
- HealthCor Management added most to Aetna Inc in Q1 2017, an estimated $92.4M increase.
- HealthCor Management's biggest Q1 2017 reduction was Quest Diagnostics, cutting an estimated $99.7M.
- HealthCor Management fully exited QIAGEN NV in Q1 2017, selling an estimated $79.9M.
- HealthCor Management's ten largest holdings make up 65% of its $2.18B portfolio in Q1 2017.
- HealthCor Management opened 13 new positions and closed 16 in Q1 2017.
- HealthCor Management's portfolio value rose 23% quarter-over-quarter to $2.18B.
Based on HealthCor Management's 13F filing for Q1 2017, filed 15 May 2017.